Linaclotide Chemical Properties

Melting point:

231-235°C (dec.)

Boiling point:

2045.0±65.0 °C(Predicted)

Density 

1.60

storage temp. 

Hygroscopic, Refrigerator, under inert atmosphere

solubility 

DMSO (Slightly, Heated), Methanol ((Slightly, Heated)), Water (Slightly, Heated)

pka

3.05±0.10(Predicted)

form 

Solid

color 

White

Stability:

Hygroscopic

InChI

InChI=1S/C59H79N15O21S6/c1-26-47(82)69-41-25-101-99-22-38-52(87)65-33(13-14-45(80)81)49(84)66-34(16-28-5-9-30(76)10-6-28)50(85)71-40(54(89)72-39(23-97-96-20-32(60)48(83)70-38)53(88)67-35(18-43(61)78)58(93)74-15-3-4-42(74)56(91)63-26)24-100-98-21-37(64-44(79)19-62-57(92)46(27(2)75)73-55(41)90)51(86)68-36(59(94)95)17-29-7-11-31(77)12-8-29/h5-12,26-27,32-42,46,75-77H,3-4,13-25,60H2,1-2H3,(H2,61,78)(H,62,92)(H,63,91)(H,64,79)(H,65,87)(H,66,84)(H,67,88)(H,68,86)(H,69,82)(H,70,83)(H,71,85)(H,72,89)(H,73,90)(H,80,81)(H,94,95)/t26-,27+,32-,33+,34-,35-,36-,37-,38-,39-,40-,41-,42-,46?/m0/s1

InChIKey

KXGCNMMJRFDFNR-VRMHCMCOSA-N

SMILES

[C@@]12(NC([C@]3([H])CSSC[C@@H](C(=O)N[C@@H](CC4C=CC(O)=CC=4)C(=O)O)NC(=O)CNC(=O)C([C@H](O)C)NC(=O)[C@]([H])(CSSC[C@@]([H])(C(=O)N[C@H](CCC(=O)O)C(N[C@@H](CC4C=CC(O)=CC=4)C(=O)N3)=O)NC(=O)[C@@H](N)CSSC1)NC(=O)[C@H](C)NC(=O)[C@]1([H])CCCN1C(=O)[C@H](CC(=O)N)NC2=O)=O)[H]

Safety Information

Hazardous Substances Data

851199-59-2(Hazardous Substances Data)

Linaclotide Usage And Synthesis

Description

In August 2012, the US FDA approved linaclotide (also referred to as MD-1100), a first-in-class, orally administered 14-amino acid peptide as a therapy for patients suffering from chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Linaclotide and its active metabolite MM-419447, which results from the cleavage of the C-terminal tyrosine residue by carboxypeptidase A, mimic the actions of the endogenous intestinal peptides guanylin (15 amino acids) and uroguanylin (16 amino acids) by activating guanylyl cyclase C (GC-C) on the intestinal epithelium. Activation of GC-C leads to increased intra- and extracellular levels of cGMP and activation of the CFTR ion channel, resulting in increased levels of HCO₃^-, Cl^-, and water in the intestinal lumen and accelerated gastrointestinal transit. Based on an in vitro assaymeasuring the accumulation of cGMP in T84 cell exposed to an agonist, the EC₅₀ of linaclotide at pH 7.0 was 99±17.5 nM. In preclinical studies in mice using the transit of activated charcoal as ameasure of efficacy, linaclotide at 100 μg/kg significantly accelerated transit compared to wild-type mice treated with charcoal only or GC-Cnullmice treatedwith and without linaclotide.118 Efficacy was also seen in rats treatedwith linaclotide atdoses of 5, 10, and 20 μg/kg. Linaclotide has been synthesized using conventional solid-phase peptide technology.

Originator

Ironwood Pharmaceuticals and Forest Pharmaceuticals (United States)

Uses

Linaclotide is a guanylate cyclase-C agonist currently being studied in Phase 3 trials for the treatment of irritable bowel syndrome with constipation.

Definition

ChEBI: Linaclotide is a fourteen-membered heterodetic cyclic peptide consisting of Cys, Cys, Glu, Tyr, Cys, Cys, Asn, Pro, Ala, Cys, Thr, Gly, Cys and Tyr residues joined in sequence and cyclised by three disulfide bonds: between Cys(1) and Cys(6), between Cys(2) and Cys(10), and between Cys(5) and Cys(13). Used for treatment of irritable bowel syndrome accompanied by constipation. It has a role as a guanylate cyclase 2C agonist.

brand name

Linzess

Biological Functions

Linaclotide works by increasing fluid in your intestines and helping speed up movement of food through the gut. Linaclotide may improve stool texture and lessen symptoms such as bloating, abdominal pain/discomfort, straining, and feelings of incomplete bowel movements.

Side effects

Side effects include:Diarrhea, abdominal pain, flatulence, abdominal distension, viral gastroenteritis, headache, upper respiratory tract infection, sinusitis

Linaclotide(851199-59-2)Related Product Information

• Goserelin
• Nafarelin
• Leuprorelin acetate
• Triptorelin
• Zafirlukast
• Tenofovir
• Elcatonin
• Somatostatin
• Leuprorelin
• Pinaverium bromide
• Mosapride
• Rifaximin
• Sofosbuvir
• Bisacodyl
• Bivalirudin
• Ziconotide Polyacetate
• Liraglutide
• Octreotide acetate